Free Trial
NASDAQ:EVO

Evotec Q1 2021 Earnings Results & Report

Evotec logo
$1.53 -0.04 (-2.55%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.53 0.00 (0.00%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evotec reported Q1 2021 earnings on May 11, 2021. The company reported EPS of $0.19, while revenue was $160.43 million.

Earnings Announcement Details

Quarter
Q1 2021
Report Date

Evotec EPS Results

Actual EPS
$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Evotec Revenue Results

Actual Revenue
$160.43 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Evotec's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Evotec Q1 2021 Earnings FAQ

Evotec (NASDAQ:EVO) reported earnings of $0.19 per share for Q1 2021. The report was announced on Tuesday, May 11, 2021.

Evotec reported revenue of $160.43 million for Q1 2021.

Evotec's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Evotec on the company's earnings history page.

Evotec Earnings Headlines

The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
Evotec Chief Scientific Officer to Depart
Evotec Announces Chief Scientific Officer Transition
Berenberg Bank Sticks to Their Hold Rating for Evotec (0IRF)
See More Evotec Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evotec? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evotec and other key companies, straight to your email.

About Evotec

Evotec (NASDAQ:EVO) SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Founded in 1993, the company supports programs from early-stage research through preclinical and clinical development, with expertise in small-molecule and biologic therapies.

Its activities include target identification and validation, screening, medicinal chemistry, pharmacology, drug manufacturing support and development services. Evotec also operates technology platforms for areas such as proteomics, data-driven drug discovery, induced pluripotent stem cells and biologics. Through its Just – Evotec Biologics business, the company develops biologic medicines and related manufacturing technologies.

Evotec serves partners internationally through research and development sites in Europe and the United States. Its collaborations span therapeutic areas including neuroscience, oncology, metabolic disease, infectious disease and immunology. The company is led by Chief Executive Officer Christian Wojczewski, who joined Evotec’s executive leadership in 2024.

View Evotec Profile